Woodland Boy Fighting Leukemia Meets Santa At Golden 1 Center North Pole CBS Sacramento [Video]

Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma. Patients enrolled were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Preliminary results of MagnetisMM-3 in patients with relapsed/refractory myeloma and no prior BCMA-targeted treatment suggest that 76 mg of elranatamb adminstered once weekly with a 2-step-up priming regimen is well tolerated, with no grade 3 cytokine release syndrome or immune effector cell-assciated neurotoxicity syndrome (ICANS) observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

We are investing $175 million over the next five years to support global, collaborative research and treatments for children's blood cancers, the LLS PedAL Master Clinical Trial, as well as widening our range of free education, 1:1 support services, financial assistance, and advocacy on behalf of all children and their families.

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the recent approval of ...